Anti-Human Fibulin-4 – Purified in vivo GOLD™ Functional Grade
Anti-Human Fibulin-4 – Purified in vivo GOLD™ Functional Grade
Product No.: F2200
- -
- -
Clone 5G11 Target Fibulin-4 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names EFEMP2; ARCL1B; FBLN4; FIBL-4; fibulin 4; MBP1; UPH1; EGF containing fibulin like extracellular matrix protein 2 Isotype Mouse IgG Applications IF Microscopy , IF Staining , IHC FFPE , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Dilution Buffer Immunogen Recombinant, human Fibulin-4 produced in E. coli BL21 cells. Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2830196 Applications and Recommended Usage? Quality Tested by Leinco WB The suggested concentration for this Fibulin-4 (Clone 5G11) antibody for use in western blotting is 1-10 μg/ml. Additional Applications Reported In Literature ? IF Staining IF Microscopy IHC FFPE Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 5G11 recognizes Human Fibulin-4. Monoclonal antibodies
raised against the purified proteins did not show any crossreactivity
with other family members.
Background There are currently seven genes in the fibulin family (Fibulin-1, 2, 3, 4, 5, 6, and 7) that are associated with elastic fibers. The fibulins are widely distributed throughout the body and are more prominent in tissues rich in elastic fibers and are often associated with vasculature and elastic tissues. Fibulin-4 appears to be the most critical member of this family of proteins in modulating elastic-fiber formation because studies have shown that fibulin-4-null mice do not produce elastic fibers at all.1 This extracellular glycoprotein has a molecular weight of approximately 49 kD, and is not only considered a structural protein of the extracellular matrix, but also a regulatory factor required for normal elastin expression in human fibroblasts.2 Due to the regulatory role of Fibulin-4, it is thought that a pathophysiological link may exist between the modulation of fibulin-4 levels and diseases, such as WBS (Williams-Beuren syndrome), that are characterized by impaired elastic-fiber formation.1 Furthermore, fibulin-4 has been shown to interact with P53, a crucial homologous protein that prevents cancer formation, and thus functions as a tumor suppressor.3 One study indicated that colon tumors were found to have approximately 2-7-fold increases of fibulin-4 mRNA expression. This suggests that the dysregulated expression of the fibulin-4 gene is associated with human colon tumourigenesis.4 Antigen Distribution Fibulin-4 is predominantly expressed in tissues rich in elastic fibers. PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology . Stem Cell References & Citations1. DiCorleto, PE. et al. (2009) Biochem J. 423(1): 79–89. 2. Kobayashi, N. et al. (2007) J Biol Chem. 282(16):11805-16. 3. Gallagher, WM. et al. (1999) Oncogene. 18(24):3608-16. 4. Gallagher, WM. et al. (2001) FEBS Lett. 489(1):59-66. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.